AR049110A1 - Compuestos terapeuticos: piridina como andamiaje estructural - Google Patents
Compuestos terapeuticos: piridina como andamiaje estructuralInfo
- Publication number
- AR049110A1 AR049110A1 ARP050102119A ARP050102119A AR049110A1 AR 049110 A1 AR049110 A1 AR 049110A1 AR P050102119 A ARP050102119 A AR P050102119A AR P050102119 A ARP050102119 A AR P050102119A AR 049110 A1 AR049110 A1 AR 049110A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- benzoylamino
- heterocyclyl
- halogenated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se preparan compuestos de formulas (1) o sus sales aceptables para uso farmacéutico, composiciones farmacéuticas que incluyen los compuestos. Son utiles en terapia, en particular en el manejo del dolor. Reivindicacion 1: Un compuesto de formula (1) o una sal aceptable para uso farmacéutico del mismo diastereomeros, enantiomeros o sus mezclas, donde: uno de A1, A2, A3 o A4 es N y los restantes son cada uno en forma independiente CR1; y R1 se selecciona en forma independiente de hidrogeno, halogeno, ciano, amino, acetilamino, hidroxilo, alcoxi, alquilo, alcoxi halogenado, alquileno, alquilo halogenado, alquenilo halogenado y NR5R6; R2 se selecciona del grupo de formulas (2), donde dicho grupo usado para definir R2 está opcionalmente sustituido con uno o más grupos seleccionados de halogeno, alquilo halogenado, alquilo, alcoxi halogenado, ciano, nitro, alcoxi, hidroxi, hidroxialquilo, amino, alquilarilo, alcoxi, alcoxialquilo, alquilcarbonilo, alcoxicarbonilo, alquilamino, aminoalquilo, alquilaminocarbonilo, heteroarilocarbonilo, heterociclilcarbonilo, arilcarbonilo, heterociclilo, cicloalquilo, heteroarilo, heteroarilalquilo, arilo, arilalquilo y -NR5R6; R3 se selecciona de hidrogeno y alquilo; R4 se selecciona de alquilo, alquenilo, cicloalquilo, cicloalquenilo, alcoxi, arilo, heteroarilo y heterociclilo; donde dichos alquilo, alquenilo, cicloalquilo, cicloalquenilo, alcoxi, arilo, heteroarilo y heterociclilo usados para definir R4 están opcionalmente sustituidos con uno o más grupos seleccionados de halogeno, alquilo halogenado, alquilo, alquicarbonilo, ciano, nitro, amino, aminoalquilo, alcoxi, alcoxi halogenado, hidroxi, alcoxialquilo, alcoxiarilo, alcoxicarbonilo, residuo heterociclilo, arilo, arilalquilo, heterocíclico-alquilo, hidroxialquilo, heteroarilo, alquilheteroarilo, arilalquilo y -NR5R6; y n se selecciona de 0, 1, 2, 3, 4 y 5; o R3 y R4 junto con el átomo de nitrogeno al que están unidos pueden formar un grupo seleccionado de heterociclilo que se fusiona opcionalmente con un anillo de cinco o seis miembros que contiene uno o más heteroátomos; donde dicho heterociclilo fusionado opcionalmente con un anillo de cinco a seis miembros que contiene uno o más heteroátomos usado para definir R3 y R4 está opcionalmente sustituido con uno o más grupos seleccionados de halogeno, alquilo halogenado, alquilo, ciano, nitro, amino, aminoalquilo, alcoxi, alcoxi halogenado, hidroxi, alcoxialquilo, alcoxiarilo, alcoxicarbonilo, residuo heterocíclico, arilo, arilalquilo, heterocíclicoalquilo, hidroxialquilo, heteroarilo, alquilheteroarilo, arilalquilo C1-6 y -NR5R6; donde cada uno de R5 y R6 se selecciona en forma independiente de hidrogeno, alquilo C1-6, alquenilo C2-6, alcoxialquilo C1-6, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, hidroxialquilo C1-6, alcoxi, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, alquilcarbonilo C1-6, heterociclilo C3-6 y heterociclil C3-6-alquilo C1-6; donde dichos alquilo C1-6, alquenilo C2-6, alcoxialquilo C1-6, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, hidroxialquilo C1-6, alcoxi, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, alquilcarbonilo C1-6, heterociclilo C3-6 y heterociclil C3-6-alquilo C1-6 usados para definir R5 y R6 están opcionalmente sustituidos con uno o más grupos seleccionados de halogeno, ciano, nitro, alcoxi C1-6, alquilo C1-6 e hidroxi; con la condicion de que cuando n = 0, entonces R4 no es tiazolilo o 5-cloropiridinilo; con la condicion adicional de que cuando R2 es fenilo entonces n = 0 y R4 no es metilo no sustituido, alquilo C3 o alquilo C4 no sustituido; y con la condicion adicional de que dicho compuesto de formula (1) no sea ninguno de: 3-(benzoilamino)-N- bencilpirin-2-carboxamida; 3-(benzoilamino)-N-piridin-3-ilpiridin-2-carboxamida; 3-(benzoilamino)-N-fenilpiridin-2-carboxamida; 3-(benzoilamino)-N-(3-nitrofenil)piridin-2-carboxamida; 3-(benzoilamino)-N-(4-metoxifenil)piridin-2-carboxamida; 3- (benzoilamino)-N-[4-(dimetilamino)fenil]piridin-2-carboxamida; N-(2-hidroxietil)-4-(2-naftoilamino)nicotinamida; 4-(benzoilamino)-N-(2-hidroxietil)nicotinamida; 3-(benzoilamino)-2,6-dimetil-N-fenilisonicotinamida; 3-(benzoilamino)-2,6-dimetil-N-(3- nitrofenil)isonicotinamida; 2-(benzoilamino)-N-[ciano(2-tienil)metil]nicotinamida; y 2-(benzoilamino)-N-[ciano(fenil)metil]nicotinamida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401345A SE0401345D0 (sv) | 2004-05-25 | 2004-05-25 | Therapeutic compounds: Pyridine as scaffold |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049110A1 true AR049110A1 (es) | 2006-06-28 |
Family
ID=32589804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102119A AR049110A1 (es) | 2004-05-25 | 2005-05-23 | Compuestos terapeuticos: piridina como andamiaje estructural |
Country Status (18)
Country | Link |
---|---|
US (1) | US20070225292A1 (es) |
EP (1) | EP1756060A1 (es) |
JP (1) | JP2008500336A (es) |
KR (1) | KR20070026540A (es) |
CN (1) | CN101001840A (es) |
AR (1) | AR049110A1 (es) |
AU (1) | AU2005247834A1 (es) |
BR (1) | BRPI0511531A (es) |
CA (1) | CA2565065A1 (es) |
IL (1) | IL179149A0 (es) |
MX (1) | MXPA06013538A (es) |
NO (1) | NO20065878L (es) |
RU (1) | RU2006145205A (es) |
SE (1) | SE0401345D0 (es) |
TW (1) | TW200607799A (es) |
UY (1) | UY28923A1 (es) |
WO (1) | WO2005115986A1 (es) |
ZA (1) | ZA200609765B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0611907D0 (en) * | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
SI1907374T1 (sl) | 2005-07-26 | 2012-11-30 | Glaxo Group Ltd | Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj |
TW200804338A (en) * | 2005-11-24 | 2008-01-16 | Astrazeneca Ab | New compounds |
GB0524814D0 (en) | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
PE20080345A1 (es) | 2006-06-28 | 2008-05-29 | Glaxo Group Ltd | Derivados de piperazina como agonistas del receptor de gpr38 |
MX2009010363A (es) | 2007-03-28 | 2009-12-04 | Abbott Lab | Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide. |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
EP2070916A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2010033543A2 (en) | 2008-09-16 | 2010-03-25 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
HUE043536T2 (hu) * | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | PDK1 inhibitorként alkalmazható heterociklusos vegyületek |
KR20140011780A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
CN104470897A (zh) * | 2012-07-19 | 2015-03-25 | 日本曹达株式会社 | 吡啶化合物和农园艺用杀菌剂 |
KR102292433B1 (ko) | 2013-11-06 | 2021-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 |
CA2929528A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Gsk-3 inhibitors |
JP2019131470A (ja) * | 2016-05-20 | 2019-08-08 | 石原産業株式会社 | N−(4−ピリジル)ベンズアミド化合物又はその塩を有効成分として含有する有害生物防除剤 |
EP3617196B1 (en) | 2017-04-27 | 2023-06-07 | Ishihara Sangyo Kaisha, Ltd. | N-(4-pyridyl) nicotinamide compound or salt thereof |
CN107880024A (zh) * | 2017-12-11 | 2018-04-06 | 张玉玲 | 一种用于治疗炎症的大麻素受体激动剂及其合成方法 |
HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
BR0207996A (pt) * | 2001-03-05 | 2004-03-02 | Du Pont | Composto, método de controle de pragas invertebradas e composição para controle das mesmas |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
-
2004
- 2004-05-25 SE SE0401345A patent/SE0401345D0/xx unknown
-
2005
- 2005-05-12 TW TW094115320A patent/TW200607799A/zh unknown
- 2005-05-20 BR BRPI0511531-0A patent/BRPI0511531A/pt not_active Application Discontinuation
- 2005-05-20 CN CNA2005800246960A patent/CN101001840A/zh active Pending
- 2005-05-20 US US11/569,315 patent/US20070225292A1/en not_active Abandoned
- 2005-05-20 WO PCT/SE2005/000753 patent/WO2005115986A1/en active Application Filing
- 2005-05-20 KR KR1020067024936A patent/KR20070026540A/ko not_active Application Discontinuation
- 2005-05-20 MX MXPA06013538A patent/MXPA06013538A/es unknown
- 2005-05-20 AU AU2005247834A patent/AU2005247834A1/en not_active Abandoned
- 2005-05-20 RU RU2006145205/04A patent/RU2006145205A/ru unknown
- 2005-05-20 JP JP2007514980A patent/JP2008500336A/ja active Pending
- 2005-05-20 CA CA002565065A patent/CA2565065A1/en not_active Abandoned
- 2005-05-20 EP EP05745177A patent/EP1756060A1/en not_active Withdrawn
- 2005-05-23 AR ARP050102119A patent/AR049110A1/es not_active Application Discontinuation
- 2005-05-25 UY UY28923A patent/UY28923A1/es not_active Application Discontinuation
-
2006
- 2006-11-09 IL IL179149A patent/IL179149A0/en unknown
- 2006-11-23 ZA ZA200609765A patent/ZA200609765B/xx unknown
- 2006-12-18 NO NO20065878A patent/NO20065878L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005247834A1 (en) | 2005-12-08 |
ZA200609765B (en) | 2008-08-27 |
BRPI0511531A (pt) | 2008-01-02 |
KR20070026540A (ko) | 2007-03-08 |
JP2008500336A (ja) | 2008-01-10 |
UY28923A1 (es) | 2005-12-30 |
MXPA06013538A (es) | 2007-01-26 |
EP1756060A1 (en) | 2007-02-28 |
TW200607799A (en) | 2006-03-01 |
RU2006145205A (ru) | 2008-06-27 |
CA2565065A1 (en) | 2005-12-08 |
CN101001840A (zh) | 2007-07-18 |
SE0401345D0 (sv) | 2004-05-25 |
US20070225292A1 (en) | 2007-09-27 |
WO2005115986A1 (en) | 2005-12-08 |
NO20065878L (no) | 2007-02-21 |
IL179149A0 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049110A1 (es) | Compuestos terapeuticos: piridina como andamiaje estructural | |
RU2006135111A (ru) | Производные тиазола | |
HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
RU2309951C2 (ru) | Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение | |
CO6270328A2 (es) | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b | |
EA200401172A1 (ru) | Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии | |
NI200600257A (es) | Nuevos compuestos. | |
PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
AR054799A1 (es) | Derivados de oxindol | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
RU2372344C2 (ru) | Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого | |
AR062299A1 (es) | Derivados de bencimidazol | |
PE20071034A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20021066A1 (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, asi como preparados farmaceuticos que las contienen | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
RU2017139564A (ru) | 5-ароматическое алкинилзамещенное бензамидное соединение и способ его получения, фармацевтическая композиция и их применение | |
AR062679A1 (es) | Derivados de eter diarilico y usos de los mismos | |
JP2010536821A5 (es) | ||
CO5611103A2 (es) | Derivados de bencensulfonamida como agentes antisicoticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |